Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on LinkedIn:
“POST 1/3
ASCO GU 2026: 10 Trials That May Redefine GU Oncology (1/3)
This was not a meeting about incremental gains.
It was about trajectory.
Let’s start with bladder cancer:
- KEYNOTE-B15 / EV-304
Perioperative Enfortumab Vedotin + Pembrolizumab vs Gem/Cis
– Could this finally displace 20 years of cisplatin dominance in MIBC? - IMvigor011
ctDNA-guided adjuvant atezolizumab
– Adjuvant immunotherapy guided by minimal residual disease detection. - NIAGARA biomarker analyses
– Liquid biopsy moving into perioperative decision-making.
Bladder cancer is shifting from chemotherapy-defined to biomarker-driven care.
Next: Prostate cancer intensification moves even earlier. ”
Other posts on Ahmet Dirican on OncoDaily.